SAN DIEGO, Oct. 29, 2015 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the quarter ended September 30, 2015 after market close on Thursday, November 5, 2015. Biocept management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
Individuals interested in participating on the conference call may do so by dialing (877) 870-4263 for domestic callers, (855)-669-9657 for Canadian callers, or (412) 317-0790 for other international callers. Those interested in listening to a webcast of the live conference call may do so by visiting http://ir.biocept.com/events.cfm.
A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering replay access code 10074637. A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.
About Biocept
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for lung, breast, colon and gastric cancers as well as melanoma, and plans to introduce CLIA-validated tests for other solid tumors in the near term. More information is available at www.biocept.com
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-hold-2015-third-quarter-conference-call-on-november-5-300167604.html
SOURCE Biocept, Inc.
